Name: Sermorelin 10mg (Research Peptide)
Brand: Verum Peptides
Price: 72 USD
Availability: InStock

Identification

Chemical name	The first twenty-nine residues of human growth hormone-releasing hormone, as a C-terminal amide
Common designations	Sermorelin; GRF(1-29) amide; GHRH(1-29)
Sequence	Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Length	29 amino acids, C-terminal amide
Substitutions	None. This is the native sequence. See section 03.
Molecular formula	C149H246N44O42S
Molecular weight	3357.9 g/mol
Expected ions	[M+3H]3+ near 1120; [M+4H]4+ near 840; [M+5H]5+ near 672; [M+6H]6+ near 561
CAS number	86168-78-7
Molecular target	Growth hormone-releasing hormone receptor, anterior pituitary somatotrophs
Oxidation-sensitive residues	Methionine at position 27; tyrosine at positions 1 and 10
Physical form	White lyophilized powder
Quantity supplied	10 mg nominal per unit
Country of manufacture	United States

Certificate of analysis - current lot

The interactive verification record is shown below, followed by the same information reproduced as text on this page and the full certificate as a document. The record does not depend on the embed loading.

Certificate of analysis - lot 92RNUA

Lot record

92RNUA

Testing laboratory	Freedom Diagnostics, United States. Independent third party, not owned by or affiliated with Verum.
Sample received	22 July 2026
Results reported	25 July 2026
Accession reference	2607220666
Analytical method	High-performance liquid chromatography with ultraviolet detection coupled to mass spectrometry (HPLC-UV / LC-MS)

Results, this lot

Identity, LC-MS	Confirmed as sermorelin, named in full on the certificate
Purity, HPLC-UV	99.63 %
Net peptide content	11.07 mg per unit
Appearance	White lyophilized powder
Mass confirmation	Four charge states observed at m/z 560.6, 672.4, 840.2 and 1119.8, all reconstructing to approximately 3357
Bacterial endotoxin	Not tested on this lot

Purity and content figures above are specific to lot 92RNUA and are not a specification carried across other lots. Four independent charge states agreeing on one molecular weight is a stronger identity argument than a single ion, because a truncated or deamidated species shifts the whole ladder rather than hiding inside one peak. Take any figure above, multiply by its charge, subtract the protons, and check that you land near 3357.

This is the sequence the others were built from

Several compounds in this catalogue act at the same receptor, and they are usually presented as a set of alternatives. They are better understood as a family with a single origin, and this is it. Sermorelin is the native fragment: the first twenty-nine residues of the endogenous hormone, amidated at the C-terminus, with nothing substituted.

Sermorelin	The native 29-residue fragment. No substitutions. Cleaved rapidly by dipeptidyl peptidase-4, which is a property of the natural sequence rather than a defect.
Modified GRF (1-29)	The same backbone carrying four substitutions that resist that cleavage. Sold across this market as CJC-1295 without DAC.
CJC-1295	The same four substitutions plus a linker that binds covalently to circulating albumin.
Tesamorelin	The full 44-residue sequence carrying an attached hydrocarbon group, rather than the 29-residue fragment.

Why that matters for study design. Each modification in that list was made to change one property, and each one changes the stimulus pattern at the receptor as a side effect. Work using an unmodified native sequence and work using a long-acting analogue are not measuring the same input, and comparisons between them have to account for that. If a design calls for the endogenous ligand fragment rather than an engineered derivative, this is that material, and it is the only entry in the family that is.

Testing scope

Panels differ between products and between lots. What follows is the scope of testing performed on this lot. Nothing is claimed unless it appears on the certificate for the lot supplied.

Performed

✓	Identity by LC-MS
✓	Purity by HPLC-UV
✓	Net peptide content
✓	Appearance by visual inspection
✓	Mass confirmation, four charge states

Not performed

-	Methionine sulfoxide content
-	Deamidation profiling
-	C-terminal amide confirmation as a separate parameter
-	Bacterial endotoxin
-	Sterility and microbial enumeration
-	Elemental impurities, residual solvents

The third entry in the right-hand column is worth noting on this molecule. A free acid at the C-terminus rather than an amide differs by about one dalton, which a four-state charge series will detect but which is not reported as a separate parameter. Where a parameter is material to intended laboratory work, purchasers should verify it independently or source material released against that specification.

Storage and laboratory handling

Lyophilized powder, transit	Stable at ambient temperature during shipping and short-term handling. Cold-chain transport is not required.
Lyophilized powder, storage	−20 °C, protected from light, container tightly closed
Solubility	Sterile laboratory-grade water or a defined aqueous buffer appropriate to the assay
Solution, storage	2 °C to 8 °C, protected from light. Prepare close to the time of use rather than holding stock.
Oxidation	A methionine and two tyrosines make this sequence less forgiving than several short peptides in this catalogue. Minimise headspace and air contact, and keep free transition metals and copper-containing preparations out of any solution carrying this peptide.
Enzymatic susceptibility	The unmodified sequence is a substrate for dipeptidyl peptidase-4. In any preparation containing serum or cell lysate, expect turnover on a timescale the engineered analogues in this family do not share.
Freeze-thaw	Avoid repeated cycles. Aliquot at first preparation where the protocol allows.
Personal protection	Handle under standard laboratory conditions with gloves, eye protection and a laboratory coat.

Preparation conditions are the responsibility of the receiving laboratory. Verum provides no protocol, no preparation instruction, and no guidance on use.

Published literature

This page carries no bibliography. The published record on this compound consists largely of clinical work generated while it held marketing authorisation, conducted in human participants using pharmaceutical-grade product manufactured to standards this material is not manufactured to. Reproducing that literature beside a research-labelled unit would misrepresent what is being sold. Researchers working on growth hormone-releasing hormone receptor pharmacology know where that record lives.

Regulatory status

This compound occupies a different position from most of the family described in section 03, and the difference is worth stating precisely.

United States, history	Held FDA approval as a prescription medicine. The approval was withdrawn in 2008. The withdrawal was a commercial decision by the sponsor and was not made on grounds of safety or effectiveness, which is a distinction the record states explicitly.
United States, present	No currently marketed approved product. A lawful route exists through a licensed compounding pharmacy on a patient-specific prescription.
By comparison	The Pharmacy Compounding Advisory Committee voted against adding CJC-1295 and ipamorelin to the 503A list in late 2024. Neither can lawfully be compounded. This compound is not in that position.
This material	Supplied as a laboratory reagent. Not manufactured to pharmaceutical standards and not a substitute for a compounded or prescribed preparation.
Athletic competition	Prohibited under World Anti-Doping Agency rules.
Status date	Accurate as of August 2026. Verify the current position independently.

We set that out because the distinction is real and is rarely drawn. Several compounds acting at this receptor have been reviewed and rejected for compounding; this one has a lawful prescription route that those do not. That is a statement about regulatory position, not about the material on this page, which is a research reagent.

Purchase eligibility

By placing an order you confirm each of the following:

✓	You are at least 21 years of age.
✓	You are a qualified researcher, or are purchasing on behalf of a research institution or commercial laboratory.
✓	The material will be used solely for in vitro laboratory research.
✓	The material will not be administered to humans or to animals, and will not be resold or transferred for any such purpose.
✓	You are responsible for compliance with all federal, state and local law governing receipt, handling, storage and use.

Confirmation is recorded at checkout against your order. Verum reserves the right to decline or cancel any order.

This substance is obtainable in the United States through licensed compounding pharmacies on a patient-specific prescription. If that is what you are looking for, a licensed prescriber is the correct route and this is not a substitute for it.

Supply

Orders placed before the daily cutoff are dispatched the same day from our United States warehouse. Domestic orders typically arrive within two business days. A tracking reference is issued by email once the consignment leaves the facility. Each unit carries a scannable code linking to the certificate for its own lot.

Not for human or veterinary use. Not for use in diagnostic or therapeutic procedures. This product is a laboratory reagent. Nothing on this page constitutes medical advice, a recommendation for personal use, or a representation that this material is safe or effective for any purpose. No statement here has been evaluated by the U.S. Food and Drug Administration.